Jun 29, 2020 06:23 PM IST The price for US private insurance companies will be $520 per vial, the drugmaker said, which equates to $3,120 per patient for a treatment course using 6 vials of remdesivir.
Jun 09, 2020 06:52 PM IST Remdesivir is the first drug to show improvement in COVID-19 in human trials, and its progress in clinical studies is being closely watched as nations look for a treatment for the disease, which has infected more than 7 million people and killed over 400,000.
Jun 02, 2020 04:46 PM IST Remdesivir is the only drug so far that has been shown to help patients with COVID-19, but Gilead and other companies are looking for ways to make it work better.
Jun 01, 2020 06:58 PM IST At Day 11, a higher proportion of patients in the 5-day treatment group achieved improvement in clinical status versus the standard of care group, Gilead said.
Apr 30, 2020 07:46 AM IST Preliminary results from a U.S. government trial showing that patients given remdesivir recovered 31% faster than those given a placebo, were hailed by Dr Anthony Fauci as "highly significant."
Apr 29, 2020 09:46 PM IST The drug is not yet licensed or approved anywhere globally and has not yet been demonstrated to be safe or effective for the treatment of COVID-19
Dec 14, 2015 09:45 AM IST Natco and Alvogen have partnered on the first abbreviated new drug application (ANDA) containing a paragraph IV certification filed with the US Food and Drug Administration (FDA) for generic versions of Tamiflu oral capsules (oseltamivir phosphate), 30 mg, 45 mg and 75 mg.
Mar 27, 2015 09:15 PM IST Sofosbuvir has high potency, high barrier to resistance, pan genotypic activity, once-daily dosage, good safety profile and the limited drug-drug interactions, which makes it a breakthrough drug in Hepatitis C treatment.
Mar 23, 2015 06:49 PM IST Dr Reddy's Laboratories today entered into an agreement with Hetero to distribute and market generic version of US-firm Gilead Sciences' Hepatitis C drug under the brand 'Resof' in India.
Mar 02, 2015 01:35 PM IST Natco will fix its own price for the generic versions, and will pay a royalty on sales to Gilead, the company said.
Aug 02, 2012 07:26 PM IST Gilead Sciences Inc signed deals with three Indian companies to drive sales and reduce manufacturing costs of low-cost generic versions of its HIV drug, Emtricitabine in developing countries.
